G Enrico Rovati

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6601308/publications.pdf

Version: 2024-02-01

115 papers	4,964 citations	117625 34 h-index	98798 67 g-index
117 all docs	117 docs citations	117 times ranked	6591 citing authors

#	Article	IF	Citations
1	Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients. Frontiers in Pharmacology, 2022, 13, 784214.	3.5	13
2	Effects of nonâ€steroidal antiâ€inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2337-2354.	5.7	9
3	Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis. Cells, 2022, 11, 725.	4.1	5
4	Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 114-130.	5.7	40
5	Formylpeptide receptors in GtoPdb v.2021.2. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	1
6	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	5.4	337
7	ERÎ±-independent NRF2-mediated immunoregulatory activity of tamoxifen. Biomedicine and Pharmacotherapy, 2021, 144, 112274.	5.6	3
8	Reciprocal interference between the NRF2 and LPS signaling pathways on the immuneâ€metabolic phenotype of peritoneal macrophages. Pharmacology Research and Perspectives, 2020, 8, e00638.	2.4	8
9	Montelukast Use Decreases Cardiovascular Events in Asthmatics. Frontiers in Pharmacology, 2020, 11, 611561.	3.5	14
10	Leukotriene receptors (version 2020.3) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	0
11	Rapid Metabolization of Protectin D1 by Î²-Oxidation of Its Polar Head Chain. Journal of Medicinal Chemistry, 2019, 62, 9961-9975.	6.4	18
12	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	5.4	519
13	Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation. Frontiers in Pharmacology, 2019, 10, 938.	3.5	13
14	Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain. Journal of Medicinal Chemistry, 2019, 62, 8443-8460.	6.4	19
15	Leukotriene receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
16	Montelukast and cardiovascular events: Insights from observational retrospective study. , 2019, , .		0
17	Formylpeptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
18	Two-pronged approach to anti-inflammatory therapy through the modulation of the arachidonic acid cascade. Biochemical Pharmacology, 2018, 158, 161-173.	4.4	41

#	Article	IF	Citations
19	Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology. Journal of Medicinal Chemistry, 2018, 61, 5758-5764.	6.4	31
20	Discovery of novel inhibitors of the phosphatase activity of the soluble epoxide hydrolase. FASEB Journal, 2018, 32, 558.3.	0.5	0
21	Impaired thromboxane receptor dimerization reduces signaling efficiency: A potential mechanism for reduced platelet function in vivo. Biochemical Pharmacology, 2017, 124, 43-56.	4.4	12
22	The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. European Journal of Clinical Pharmacology, 2017, 73, 799-809.	1.9	49
23	The DRY motif and the four corners of the cubic ternary complex model. Cellular Signalling, 2017, 35, 16-23.	3.6	14
24	Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk. Current Medicinal Chemistry, 2017, 24, 3218-3230.	2.4	6
25	Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies. Frontiers in Pharmacology, 2016, 7, 299.	3.5	28
26	Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure. Journal of Medicinal Chemistry, 2016, 59, 7152-7166.	6.4	49
27	In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition. Pharmacological Research, 2016, 103, 132-143.	7.1	10
28	A potential role of PUFAs and COXIBs in cancer chemoprevention. Prostaglandins and Other Lipid Mediators, 2015, 120, 97-102.	1.9	14
29	Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: Signaling through the CysLT2 receptor. Prostaglandins and Other Lipid Mediators, 2015, 120, 115-125.	1.9	19
30	Transcellular biosynthesis of eicosanoid lipid mediators. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 377-382.	2.4	71
31	The DRY motif at work: the P2Y12 receptor case. Journal of Thrombosis and Haemostasis, 2014, 12, 713-715.	3.8	4
32	Functional Characterization of E. coli LptC: Interaction with LPS and a Synthetic Ligand. ChemBioChem, 2014, 15, 734-742.	2.6	16
33	Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents. Pulmonary Pharmacology and Therapeutics, 2014, 27, 10-16.	2.6	30
34	Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. British Journal of Pharmacology, 2014, 171, 3551-3574.	5.4	173
35	Pharmacogenetics of the G Protein-Coupled Receptors. Methods in Molecular Biology, 2014, 1175, 189-242.	0.9	31
36	Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke. Medicinal Research Reviews, 2013, 33, 364-438.	10.5	93

#	Article	IF	Citations
37	Full and Partial Agonists of Thromboxane Prostanoid Receptor Unveil Fine Tuning of Receptor Superactive Conformation and G Protein Activation. PLoS ONE, 2013, 8, e60475.	2.5	12
38	Designing Multitarget Antiâ€inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonistsâ€“COXâ€2 Inhibitors. ChemMedChem, 2012, 7, 1647-1660.	3.2	28
39	International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions. Pharmacological Reviews, 2011, 63, 539-584.	16.0	134
40	Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT 2 receptor. FASEB Journal, 2011, 25, 3519-3528.	0.5	27
41	Light on the structure of thromboxane A2 receptor heterodimers. Cellular and Molecular Life Sciences, 2011, 68, 3109-3120.	5.4	23
42	Superactive mutants of thromboxane prostanoid receptor: functional and computational analysis of an active form alternative to constitutively active mutants. Cellular and Molecular Life Sciences, 2010, 67, 2979-2989.	5.4	14
43	A role for inflammatory mediators in heterologous desensitization of CysLT1 receptor in human monocytes. Journal of Lipid Research, 2010, 51, 1075-1084.	4.2	10
44	Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. Trends in Pharmacological Sciences, 2010, 31, 102-107.	8.7	40
45	Heterotrimeric G proteins demonstrate differential sensitivity to Î²-arrestin dependent desensitization. Cellular Signalling, 2009, 21, 1135-1142.	3.6	10
46	Antagonism of thromboxane receptors by diclofenac and lumiracoxib. British Journal of Pharmacology, 2008, 153, 1763-1763.	5.4	1
47	Montelukast inhibits tumour necrosis factorâ€Î±â€mediated interleukinâ€8 expression through inhibition of nuclear factorâ€ºB p65â€associated histone acetyltransferase activity. Clinical and Experimental Allergy, 2008, 38, 805-811.	2.9	45
48	The Highly Conserved DRY Motif of Class A G Protein-Coupled Receptors: Beyond the Ground State. Molecular Pharmacology, 2007, 71, 959-964.	2.3	322
49	A functional G300S variant of the cysteinyl leukotriene 1 receptor is associated with atopy in a Tristan da Cunha isolate. Pharmacogenetics and Genomics, 2007, 17, 539-549.	1.5	33
50	Cysteinyl-Leukotriene Receptors and Cellular Signals. Scientific World Journal, The, 2007, 7, 1375-1392.	2.1	47
51	Cysteinylâ€leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends. Medicinal Research Reviews, 2007, 27, 469-527.	10.5	150
52	Antagonism of thromboxane receptors by diclofenac and lumiracoxib. British Journal of Pharmacology, 2007, 152, 1185-1195.	5.4	29
53	Cysteinyl-leukotrienes in the regulation of Î²2-adrenoceptor function: an in vitro model of asthma. Respiratory Research, 2006, 7, 103.	3.6	21
54	CysLT1 receptor-induced human airway smooth muscle cells proliferation requires ROS generation, EGF receptor transactivation and ERK1/2 phosphorylation. Respiratory Research, 2006, 7, 42.	3.6	60

#	Article	IF	Citations
55	The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO Journal, 2006, 25, 4615-4627.	7.8	380
56	G-Protein-Coupled Receptors and Asthma Endophenotypes. Molecular Diagnosis and Therapy, 2006, 10, 353-366.	3.8	19
57	Cysteinyl-Leukotriene Receptor Antagonists: Present Situation and Future Opportunities. Current Medicinal Chemistry, 2006, 13, 3213-3226.	2.4	71
58	Pharmacological Characterization of 2NTX-99 [4-Methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a Potential Antiatherothrombotic Agent with Antithromboxane and Nitric Oxide Donor Activity in Platelet and Vascular Preparations. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 830-837.	2.5	9
59	The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo. Pharmacological Reviews, 2006, 58, 463-487.	16.0	431
60	CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochemical Pharmacology, 2005, 71, 115-125.	4.4	67
61	Age-related decline in RACK-1 expression in human leukocytes is correlated to plasma levels of dehydroepiandrosterone. Journal of Leukocyte Biology, 2005, 77, 247-256.	3.3	31
62	Thromboxane Prostanoid Receptor Signals Through GiProtein to Rapidly Activate Extracellular Signalâ€“Regulated Kinase in Human Airways. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 326-333.	2.9	25
63	CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation. Journal of Cell Science, 2005, 118, 5625-5636.	2.0	59
64	International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor. Pharmacological Reviews, 2004, 56, 149-157.	16.0	54
65	Mutational Analysis of the Highly Conserved ERY Motif of the Thromboxane A2 Receptor: Alternative Role in G Protein-Coupled Receptor Signaling. Molecular Pharmacology, 2004, 66, 880-889.	2.3	54
66	CysLT1 signal transduction in differentiated U937 cells involves the activation of the small GTP-binding protein Ras. Biochemical Pharmacology, 2004, 67, 1569-1577.	4.4	28
67	Leukotriene modifiers in asthma management. IDrugs: the Investigational Drugs Journal, 2004, 7, 659-66.	0.7	2
68	Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells. Prostaglandins and Other Lipid Mediators, 2003, 71, 235-251.	1.9	29
69	Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant role in proliferation. European Journal of Pharmacology, 2003, 474, 149-159.	3.5	41
70	Pranlukast. Drugs, 2003, 63, 991-1019.	10.9	58
71	Developmental Expression of Heteromeric Nicotinic Receptor Subtypes in Chick Retina. Molecular Pharmacology, 2003, 63, 1329-1337.	2.3	30
72	Bell-shaped curves for prostaglandin-induced modulation of adenylate cyclase: two mutually opposing effects. European Journal of Pharmacology, 2002, 454, 107-114.	3.5	17

#	Article	IF	Citations
73	Pharmacological differences among CysLT1 receptor antagonists with respect to LTC4 and LTD4 in human lung parenchyma. Biochemical Pharmacology, 2002, 63, 1537-1546.	4.4	31
74	Leukotrienes as Mediators of Asthma. Pulmonary Pharmacology and Therapeutics, 2001, 14, 3-19.	2.6	102
75	PURINES 2000 meeting: Biochemical, pharmacological and clinical perspectives. Drug Development Research, 2001, 52, iv-iv.	2.9	0
76	Two distinct P2Y receptors are involved in purine- and pyrimidine-evoked Ca2+ elevation in mammalian brain astrocytic cultures. Drug Development Research, 2001, 52, 122-132.	2.9	4
77	Leukotriene D4-Induced Activation of Smooth-Muscle Cells From Human Bronchi Is Partly Ca2 +-Independent. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 266-272.	5.6	38
78	Binding to Cysteinyl-Leukotriene Receptors. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S46-S50.	5.6	20
79	The many faces of binding artefacts. Trends in Pharmacological Sciences, 2000, 21, 168-169.	8.7	2
80	A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma. Molecular Pharmacology, 2000, 57, 1182-9.	2.3	24
81	Expression of Prostacyclin Receptors in Luteinizing Hormone-Releasing Hormone Immortalized Neurons: Role in the Control of Hormone Secretion**This work was supported by funds from Telethon (Grant E.523), by CNR through the Project Aging (95.01020PF40), and by MURST.. Endocrinology, 1999, 140, 171-177.	2.8	10
82	Receptors for Cysteinyl-Leukotrienes in Human Cells. Advances in Experimental Medicine and Biology, 1999, 447, 165-170.	1.6	3
83	Expression of Prostacyclin Receptors in Luteinizing Hormone-Releasing Hormone Immortalized Neurons: Role in the Control of Hormone Secretion. Endocrinology, 1999, 140, 171-177.	2.8	2
84	Evaluation of the Pharmacological Activity of the Pure Cysteinyl-Leukotriene Receptor Antagonists CGP 45715A (Iralukast) and CGP 57698 in Human Airways. Advances in Experimental Medicine and Biology, 1999, 469, 313-318.	1.6	0
85	Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. British Journal of Pharmacology, 1998, 123, 590-598.	5.4	17
86	4-Oxystilbene compounds are selective ligands for neuronal nicotinic Î± Bungarotoxin receptors. British Journal of Pharmacology, 1998, 124, 1197-1206.	5.4	51
87	Ligand-binding studies: old beliefs and new strategies. Trends in Pharmacological Sciences, 1998, 19, 365-369.	8.7	34
88	Identification and Characterization of Two Cysteinyl-Leukotriene High Affinity Binding Sites with Receptor Characteristics in Human Lung Parenchyma. Molecular Pharmacology, 1998, 53, 750-758.	2.3	34
89	Cysteinyl-leukotriene receptors and transduction mechanisms in airway cells. , 1998, , 35-42.		0
90	Working Hypothesis on the Classification of Cys-Leukotriene Receptors in Airways. Annals of the New York Academy of Sciences, 1997, 812, 169-170.	3.8	2

#	Article	IF	Citations
91	More on the classification of cysteinyl leukotriene receptors. Trends in Pharmacological Sciences, 1997, 18, 148.	8.7	12
92	Receptors and Second Messengers for Cys-Leukotrienes. , 1996, , 127-136.		4
93	KINFIT II: a nonlinear least-squares program for analysis of kinetic binding data. Molecular Pharmacology, 1996, 50, 86-95.	2.3	6
94	Adenosine A1 receptors in rat brain synaptosomes: Transductional mechanisms, effects on glutamate release, and preservation after metabolic inhibition. Drug Development Research, 1995, 35, 119-129.	2.9	5
95	Prostacyclin effects on adenylate cyclase in platelets and vascular smooth muscle: interaction with an inhibitory receptor or partial agonism?. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, 1995, 23, 263-5.	0.2	5
96	Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. European Journal of Pharmacology, 1994, 266, 219-227.	2.6	35
97	Rovati and Nicosia reply. Trends in Pharmacological Sciences, 1994, 15, 321-322.	8.7	7
98	Lower efficacy: interaction with an inhibitory receptor or partial agonism?. Trends in Pharmacological Sciences, 1994, 15, 140-144.	8.7	67
99	Prolonged agonist exposure induces imbalance of A1 and A2 receptor-mediated functions in rat brain slices. Drug Development Research, 1993, 28, 364-368.	2.9	9
100	Rational Experimental Design and Data Analysis for Ligand Binding Studies: Tricks, Tips and Pitfalls. Pharmacological Research, 1993, 28, 277-300.	7.1	14
101	MacELLIPSE, A Graphical Aid to the Problem of the Joint Confidence Region: a Practical Example for Ligand Binding Experiments. Pharmacological Research, 1993, 28, 351-358.	7.1	4
102	Binding Characteristics of Hypothalamic Mu Opioid Receptors throughout the Estrous Cycle in the Rat. Neuroendocrinology, 1993, 58, 366-372.	2.5	79
103	Identification of hydropathically complementary putative contact sequences within epidermal growth factor (EGF) and the EGF receptor. Life Sciences, 1992, 51, 37-47.	4.3	3
104	Non-serotonergic 3H-ketanserin binding sites in human platelets: Characteristics and interaction with calcium antagonists. Pharmacological Research, 1992, 26, 187-199.	7.1	5
105	Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Biochemical Pharmacology, 1992, 44, 1411-1415.	4.4	20
106	Prolonged in vitro exposure of rat brain slices to adenosine analogues: Selective desensitization of adenosine A1 but not A2 receptors. European Journal of Pharmacology, 1992, 227, 317-324.	2.6	60
107	Computerized Optimization of Experimental Design for Estimating Binding Affinity and Binding Capacity in Ligand Binding Studies. Methods in Neurosciences, 1992, 10, 175-195.	0.5	1
108	Eicosanoid release and mepyramine, LTC4 and LTD4 binding in passively sensitized human lung parenchyma in vitro. Biochemical Pharmacology, 1991, 42, 419-424.	4.4	2

#	Article	IF	Citations
109	A versatile implementation of the Gauss-Newton minimization algorithm using MATLAB for Macintosh microcomputers. Computer Methods and Programs in Biomedicine, 1990, 32, 161-167.	4.7	2
110	DESIGN: Computerized optimization of experimental design for estimating Kd and Bmax in ligand binding experiments. Analytical Biochemistry, 1990, 184, 172-183.	2.4	36
111	Identification of heterogeneity of leukotriene receptors in membranes of human lung using a computerized modelling approach. Pharmacological Research, 1990, 22, 435.	7.1	0
112	Optimization of Experimental Design for Ligand Binding Studies: Improved Estimation of Affinity and Binding Capacity. Pharmacological Research, 1989, 21, 71-72.	7.1	3
113	DESIGN: Computerized optimization of experimental design for estimating Kd and Bmax in ligand binding experiments. Analytical Biochemistry, 1988, 174, 636-649.	2.4	42
114	Identification of specific binding sites for leukotriene C4 in membranes from human lung. Biochemical Pharmacology, 1985, 34, 2831-2837.	4.4	41
115	Prostacyclin-lipoprotein interactions. Biochemical Pharmacology, 1985, 34, 2451-2457.	4.4	24